"Rare brain" conference
Colleagues from the Institute of Cognitive Neuroscience took part in the first online conference in Russia dedicated to making the neuroscience advancments accessible to people with neurological differences.
This large group includes children and adults with autism spectrum disorders, ADHD, people with dyslexia and dysgraphia, deaf-blind people, patients with rare diseases: epidermolysis bullosa, ichthyosis, Duchenne muscular dystrophy, osteogenesis imperfecta and other features.
The conference took place on March 17 and 18, 2022 in an online format. More than 40 experts in neurophysiology, neurology, psychiatry, clinical psychology and rehabilitation contributed on the topics such as:
- Trends and innovations in neurosciences
- Latest technologies in the service of cognitive rehabilitation
- Behavioral disorders and emotional problems of people with neurological differences
- Features of development and behavior in patients with rare (orphan) diseases
- Sexuality in neurodivergent adolescents and adults
Experts in crisis psychology shared recommendations for maintaining mental health in difficult situations.
Some prominent speakers included:
— Mikhail Lebedev, Professor, Center for Neurobiology and Neurorehabilitation, Skolkovo Institute of Science and Technology
— Vasily Klyucharev, Professor, Director of the Institute of Cognitive Neuroscience, National Research University Higher School of Economics
— Anna Bitova, Director of the Center for Curative Pedagogics "Special Childhood"
- and many others
Funds-organizers: Butterfly Children, Gordey, Live Now, Fragile People, AiF. Kind heart, Connection.
The conference was also supported by the information and educational project on orphan diseases "Help for the Rare", the publishing group "Alpina Publisher", an educational project for children and parents in the field of neurodevelopment of speech and cognitive rehabilitation of the "Butterfly Children" Foundation Neuro Method, pharmaceutical companies PTC Therapeutics, Pfizer, as well as "EVER Pharma".